Lewes, DE -- (SBWIRE) -- 10/02/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), Nektar Therapeutics (NASDAQ:NKTR), Cell Therapeutics Inc (NASDAQ:CTIC), Exelixis, Inc. (NASDAQ:EXEL).
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), increased0.12% and closed at $8.50 on a traded volume of 2.37 million shares, in comparison to 5.07 million shares of average trading volume. So far this year, the stock is up over 192.1%.
The company has a total market capitalization of $806.44 million.
Will ASTX Continue To Move Higher? Find Out Here
Nektar Therapeutics (NASDAQ:NKTR), soared0.05% and closed at $10.45 on a traded volume of 2.34 million shares, whereas its average trading volume is 1.42 million shares. In the last three months, the stock is down -12.63%. The Intra-day range for the stock is $10.09 and $10.59.
Will NKTR Continue To Move Higher? Find Out Here
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is consisted of early to late stage drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology.
Cell Therapeutics Inc (NASDAQ:CTIC), jumped up2.41% and closed at $1.66. So far in three months, the stock is up 66.99%. The 52-week range for the stock is $0.97 and $2.75 and during the previous trading session it marked$1.70 as its highest price. The stock initially exchanged hands with a price of $1.63 and the overall traded volume that day was 2.31 million shares.
Will CTIC Continue To Move Higher? Find Out Here
Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer.
Exelixis, Inc. (NASDAQ:EXEL) after opening its shares at the price of $5.84, jumped up1.72% to close the day at $5.92. The stock ended on a traded volume of 2.25 million shares, in comparison to 1.99 million shares of average trading volume. The 52-week range for the stock is $4.29 and $5.96 and during the previous trading session the stock scored the highest price of $5.92. It started the day at $5.84.
Why Should Investors Buy EXEL After The Recent Gain? Just Go Here and Find Out.
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds.
About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/